2025/11/20 by Robert Bissonnette, Étienne Saint‐Cyr Proulx, Joel Corrêa da Rosa +9 · 1 voice
Medicine · #Allergic Rhinitis and Sensitization #Asthma and respiratory diseases #Dermatology and Skin Diseases
paper · pdf · doi:10.1016/j.jid.2025.10.613
openalex created_date 2025/11/20 · openalex publication_date 2025/11/20 · openalex updated_date 2026/07/25
To address the need for rapid reduction of atopic dermatitis (AD) clinical manifestations, this study investigated the time course of the effects of ruxolitinib (selective JAK1/JAK2 inhibitor) cream on itch and associated changes in skin and serum biomarkers in adults with AD. In the open-label SCRATCH-AD study (NCT04839380), patients with AD, an Investigator's Global Assessment score ≥2, and a Peak Pruritus Numerical Rating Scale score ≥4 applied 1.5% ruxolitinib cream to all affected areas (except palms, soles, scalp, genitals, and folds; ≤20% body surface area) twice daily for 28 days. Among 46 patients, the mean change from baseline in Peak Pruritus Numerical Rating Scale was -3.4 on day 2 (worst itch, 24-hour recall; primary endpoint) and -5.7 on day 29. Mean change from baseline in modified Peak Pruritus Numerical Rating Scale (current itch) was -2.3 by 15 minutes. Skin (sampled with tape strips) and serum biomarkers associated with AD, such as CCL17 and matrix metalloproteinase 12, were downregulated with ruxolitinib cream and correlated with improvements in disease and symptom severity. There were no serious treatment-emergent adverse events. In summary, patients with AD who applied 1.5% ruxolitinib cream experienced rapid and sustained improvement in itch and clinical improvements that correlated with changes in AD biomarkers.